MLYS (STOCKS)
Mineralys Therapeutics, Inc. Common Stock
$23.920000
+0.300000 (+1.27%)
Prev close: $23.620000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Jon Congleton
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2,108.75M
- Employees
- 51
- P/E (TTM)
- -11.62
- P/B (TTM)
- 3.05
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
9
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.47 | $-0.47 | +0.0005 | +0.11% |
|
Dec 2025 (Q4)
|
$-0.40 | $-0.54 | +0.1435 | +26.40% |
|
Sep 2025 (Q3)
|
$-0.52 | $-0.63 | +0.1124 | +17.77% |
|
Jun 2025 (Q2)
|
$-0.66 | $-0.73 | +0.0744 | +10.13% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $19.72M |
| Operating Expenses | $171.50M |
| Research and Development | $118.50M |
| Other Operating Expenses | $53.00M |
| Operating Income/Loss | -$171.50M |
| Income/Loss From Continuing Operations After Tax | -$151.78M |
| Income/Loss From Continuing Operations Before Tax | -$151.78M |
| Net Income/Loss | -$151.78M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$151.78M |
| Net Income/Loss Available To Common Stockholders, Basic | -$151.78M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.00 |
| Diluted Earnings Per Share | -$2.00 |
| Basic Average Shares | 223,403,274 |
| Diluted Average Shares | 223,403,274 |
| Assets | $652.86M |
| Current Assets | $652.47M |
| Noncurrent Assets | $392.00K |
| Fixed Assets | $32.00K |
| Other Non-current Assets | $360.00K |
| Liabilities | $14.72M |
| Current Liabilities | $14.72M |
| Accounts Payable | $1.12M |
| Other Current Liabilities | $13.60M |
| Noncurrent Liabilities | $0.00 |
| Equity | $638.14M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $638.14M |
| Liabilities And Equity | $652.86M |
| Net Cash Flow From Operating Activities | -$136.40M |
| Net Cash Flow From Operating Activities, Continuing | -$136.40M |
| Net Cash Flow From Investing Activities | -$341.82M |
| Net Cash Flow From Investing Activities, Continuing | -$341.82M |
| Net Cash Flow From Financing Activities | $425.99M |
| Net Cash Flow From Financing Activities, Continuing | $425.99M |
| Net Cash Flow | -$52.23M |
| Net Cash Flow, Continuing | -$52.23M |
| Comprehensive Income/Loss | -$151.78M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$151.78M |
| Other Comprehensive Income/Loss | $0.00 |